This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

12 Dec 2011

Novozymes Expands Partnership with Upperton

Combining Novozymes' IP and expertise around the albumin molecules with Upperton’s rP-conjugate albumin conjugation chemistry knowledge, enables the companies to design and implement the best chemical linking approach for their molecule.

Danish firm Novozymes Biopharma has expanded its partnership with UK-based research and development company, Upperton, to offer a new albumin conjugation solution.


By linking drugs to Novozymes’ new Recombumin Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result, manufacturers can benefit from tailoring and controlling the half-life of drugs to fit a patient’s medical needs.


According to Novozymes Biopharma, Upperton has demonstrated that proteins, peptides and small molecule APIs can be covalently attached to recombinant human albumin using a range of chemistries. Additionally, once drugs have been linked to the recombinant human albumin carrier, they exhibi

Related News